Ramaprasad Srinivasan, M.D., Ph.D.


Urologic Oncology Branch


Building 10 - Hatfield CRC, Room 1-5940
Bethesda, MD 20892




Dr. Srinivasan is a Staff Clinician in the Urologic Oncology Branch, National Cancer Institute (NCI). He obtained his M.D., from the Bangalore Medical College in India and completed his Ph.D., in biomedical sciences at the University of Texas MD Anderson Cancer Center in Houston. He came to NCI in 1999 after completing his Internal Medicine Residency training at the University of Texas Health Science Center-Houston, to pursue a fellowship in Medical Oncology/Hematology. After completing his fellowship, he joined the Urologic Oncology Branch, where he is developing treatment strategies and clinical trials for patients with both hereditary and non-hereditary forms of kidney cancer. He is currently investigating a variety of newer 'targeted' agents in clear cell and papillary kidney cancer, as well as hereditary kidney cancer syndromes such as von Hippel-Lindau, hereditary leiomyomatosis and renal cell cancer and hereditary papillary renal cell cancer (HPRC).

Selected Publications

  1. Ball MW, Singer EA, Srinivasan R. Renal cell carcinoma: molecular characterization and evolving treatment paradigms. Curr Opin Oncol. 2017.

  2. Shuch B, Agochukwu N, Ricketts CJ, Vocke CD, Gautam R, Merino M, Linehan WM, Srinivasan R. Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer. J Clin Oncol. 2016;34(9):e76-9.

  3. Sourbier C, Ricketts CJ, Matsumoto S, Crooks DR, Liao PJ, Mannes PZ, Yang Y, Wei MH, Srivastava G, Ghosh S, Chen V, Vocke CD, Merino M, Srinivasan R, Krishna MC, Mitchell JB, Pendergast AM, Rouault TA, Neckers L, Linehan WM. Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer. Cancer Cell. 2014;26(6):840-850.

  4. Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol. 2014;32(5):431-7.

  5. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181-6.

This page was last updated on September 12th, 2019